Navigation Links
Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009
Date:5/6/2009

failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the possibility that the NDA submission will not be completed in the second quarter of 2009, that priority review will not be granted by the FDA and that a decision by the FDA is not rendered in late 2009, the possibility that we may not receive all of the additional amount owed to us by Spectrum, our ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in our filings with the Securities and Exchange Commission including, without limitation, our most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, we do not intend to update or alter our forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    F: 206.272.4434
    E: media@ctiseattle.com
    www.celltherapeutics.com/media.htm

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.celltherapeutics.com/investors.htm

                                              Three Months Ended
                                                   March 31,
                                                   ---------
                                                2009        2008
                                                ----        ----
    Revenues:
      Product sales                               $-      $3,374
      License and contract revenue                20          20
                                           
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement for new Oxycyte-based Cosmetic Gel
2. Royer Animal Health Enters Into Exclusive Agreement With MWI Veterinary Supply for U.S. Distribution of Next-Generation Therapeutics to Treat Cancer and Infections
3. Cornerstone Therapeutics to Host First Quarter 2009 Conference Call
4. Prime Therapeutics Announces Departure of President and Chief Executive Officer Timothy Dickman
5. InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer
6. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
7. TorreyPines Therapeutics, Inc. Hires Advisor to Evaluate Strategic Alternatives
8. Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide
9. Intrinsic Therapeutics Announces CE Mark for Barricaid Anular Prosthesis
10. Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone
11. Former Executive at Genzyme Corp. and Osiris Therapeutics, Inc. to Head Business Advisory Board at Rx for Africa, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... study has found that India,s shocking rates of suicide ... who are clinging to tiny smallholdings less than ... such as cotton and coffee, that are highly susceptible ... range of previous case studies that point to a ... the ,liberalisation, of the nation,s economy during the 90s. ...
(Date:4/17/2014)... Researchers from LSTM have called for more research ... coinfection in children in sub-Saharan Africa. In a ... LSTM,s Professor Russell Stothard, working with colleagues in ... Western Reserve University, in Cleveland Ohio, University of ... previous research into the joint burden of HIV/AIDS ...
(Date:4/16/2014)... , DOWNERS GROVE, Ill. April 16, 2014 ... of surveillance colonoscopy in average-risk patients with one to ... about 90 percent of cases. This may be an ... multicenter endoscopic database study to quantify adherence to guidelines ...
(Date:4/15/2014)... by the RECIST Working Group published in the European ... more refined categorization of tumor response or various aspects of ... database. They found that modeling target lesion tumor growth ... beyond that of the other components of progression. The RECIST ...
(Date:4/14/2014)... USA The International and American Associations for Dental ... Diseases and Their Dental, Oral, and Craniofacial Manifestations." The ... Burke, Alison M. Boyce, Michael Collins, Brian L. Foster, ... Martha J. Somerman and J. Timothy Wright is published ...
Breaking Medicine News(10 mins):Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Can refined categorization improve prediction of patient survival in RECIST 1.1? 2Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2
... from academic and business leaders, technologists, physicians, ... In response to President Obama,s call ... for Connected Health, a division of Partners ... in December, to explore the opportunities and ...
... patients, help rural broadband developmentWASHINGTON, Jan. 22 An ... protect patients from medical errors was adopted by unanimous ... & Commerce Committee,s markup of the Democrats, $825 billion ... secure electronic system to store our medical records, it ...
... 23 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced ... Sclerosis taking,place this week in Santa Fe, New Mexico. , ... Time: 2:30 - 4:30pm , ... MS , Presentation Title: The orally ...
... DEPTFORD, N.J., Jan. 23 In an effort to ... and Licensed Practical Nurses are set to participate in ... Innova Hammonton scheduled to begin at 6 a.m. on ... The National Union of Hospital and Health Care Employees ...
... open here in March, will provide clients with the opportunity in ... team of expert physicians at a state-of-the-art evaluation facility. , ... ... Health Evaluation Center (WHEC), set to open here in March, will ...
... Stethoscope.com announced today the implementation of customer product reviews for the ... ... Wayland, MA (PRWEB) January 23, 2009 -- Stethoscope.com ... full line of medical products offered on their website., , ,"We ...
Cached Medicine News:Health News:Healthcare Reform Should Include Connected Health and Participatory Medicine, Says Report Submitted to President Obama by Center for Connected Health 2Health News:Healthcare Reform Should Include Connected Health and Participatory Medicine, Says Report Submitted to President Obama by Center for Connected Health 3Health News:New Williamsburg Health Evaluation Center, The Ultimate Investment In Future Health And Well-Being, Set To Open In March 2
(Date:1/15/2014)... 2014 As health officials across the Midwest warn against ... in Michigan will offer free diagnostic ... Meijer pharmacists to administer tests and, in some cases, fill ... participating in the study. The Grand ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... seats and large backrests with lumbar support ... and casters and glides. • Choose the ... variety of environments including: industry, education, laboratory, ... office. • With cast aluminum base • ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With cast ...
Medicine Products: